Related Experiment Video
Updated: May 16, 2025
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Molecular testing and targeting for solid tumors with CNS metastases
Kate E Therkelsen1, Toni Cao1, Meaghan Roy-O'Reilly1
1Division of Neuro-oncology, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
Abstract:
The landscape of molecular testing in solid tumors is rapidly expanding. Understanding testing options and limitations can inform treatment decisions for many patients with metastatic disease to the central nervous system (CNS).
Insights
Molecular testing for solid tumors is growing. Understanding these tests helps guide treatment for patients with metastatic brain tumors.
Area of Science:
- Oncology
- Molecular Diagnostics
- Neuro-oncology
Background:
- The field of molecular testing for solid tumors is evolving quickly.
- Accurate molecular profiling is crucial for targeted therapy selection.
Purpose of the Study:
- To review current molecular testing options for solid tumors.
- To highlight the implications of these tests for central nervous system (CNS) metastases.
- To inform clinical decision-making in neuro-oncology.
Main Methods:
- Literature review of recent advancements in molecular diagnostics for solid tumors.
- Analysis of testing methodologies and their clinical utility.
- Discussion of challenges and limitations in testing CNS metastases.
Main Results:
- Molecular testing provides actionable insights for a growing number of solid tumors.
- Specific genomic alterations can be targeted with approved therapies.
- Testing limitations exist, particularly for tissue acquisition and analysis in the CNS.
Conclusions:
- Comprehensive molecular testing is essential for optimizing treatment strategies in patients with solid tumors, including those with CNS metastases.
- Continued research is needed to overcome current testing challenges and expand therapeutic options.
